Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform

Abstract Background Plasma biomarkers for Alzheimer's disease (AD) are a promising tool for accessible and accurate biological diagnostics. However, data in clinical practice are needed to better understand their diagnostic and prognostic ability in memory unit patients. Methods We analyzed pla...

Full description

Saved in:
Bibliographic Details
Main Authors: Francisco Martínez-Dubarbie, Armando Guerra-Ruiz, Sara López-García, Carmen Lage, Marta Fernández-Matarrubia, Álvaro Nevado-Cáceres, María Rivera-Sánchez, Andrea Valera-Barrero, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Marcos López-Hoyos, Juan Irure-Ventura, Enrique Marco de Lucas, Marta Drake-Pérez, Nancy Heidy Cahuana-Santamaría, María Teresa García-Unzueta, Pascual Sánchez-Juan, Eloy Rodríguez-Rodríguez
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13195-025-01719-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850208637630283776
author Francisco Martínez-Dubarbie
Armando Guerra-Ruiz
Sara López-García
Carmen Lage
Marta Fernández-Matarrubia
Álvaro Nevado-Cáceres
María Rivera-Sánchez
Andrea Valera-Barrero
Ana Pozueta-Cantudo
María García-Martínez
Andrea Corrales-Pardo
María Bravo
Marcos López-Hoyos
Juan Irure-Ventura
Enrique Marco de Lucas
Marta Drake-Pérez
Nancy Heidy Cahuana-Santamaría
María Teresa García-Unzueta
Pascual Sánchez-Juan
Eloy Rodríguez-Rodríguez
author_facet Francisco Martínez-Dubarbie
Armando Guerra-Ruiz
Sara López-García
Carmen Lage
Marta Fernández-Matarrubia
Álvaro Nevado-Cáceres
María Rivera-Sánchez
Andrea Valera-Barrero
Ana Pozueta-Cantudo
María García-Martínez
Andrea Corrales-Pardo
María Bravo
Marcos López-Hoyos
Juan Irure-Ventura
Enrique Marco de Lucas
Marta Drake-Pérez
Nancy Heidy Cahuana-Santamaría
María Teresa García-Unzueta
Pascual Sánchez-Juan
Eloy Rodríguez-Rodríguez
author_sort Francisco Martínez-Dubarbie
collection DOAJ
description Abstract Background Plasma biomarkers for Alzheimer's disease (AD) are a promising tool for accessible and accurate biological diagnostics. However, data in clinical practice are needed to better understand their diagnostic and prognostic ability in memory unit patients. Methods We analyzed plasma phosphorylated tau at threonine 217 (p-tau217) and neuroflament light chain (NfL) levels and AD cerebrospinal fluid (CSF) biomarkers in a group of 493 subjects using the Lumipulse G600II platform. The sample includes 340 patients from our memory unit (142 dementia, 186 mild cognitive impairment, and 12 with subjective complaints) and 153 cognitively unimpaired volunteers. We have correlated plasma and CSF biomarkers; we have analyzed plasma biomarker levels as a function of clinical diagnosis, cognitive status and amyloid status. We have also studied the ability of p-tau217 to discriminate between amyloid-positive and -negative subjects according to CSF using receiver operating characteristic curves. Results Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho = -0.75; p-value < 0.001), p-tau181 (r = 0.66; p-value < 0.001), and t-tau (r = 0.59; p-value < 0.001). Plasma NfL correlated with CSF NfL (r = 0.48; p-value < 0.001). By clinical diagnosis, plasma p-tau217 levels showed to be higher in AD patients than in healthy controls (difference = 0.63 pg/ml; p-value < 0.001), FTD (difference = 0.60 pg/ml; p-value < 0.001), and nondegenerative dementias (difference = 0.61 pg/ml; p-value < 0.001). Plasma p-tau217 showed an area under the curve of 0.95 to discriminate between A + and A- subjects (95%CI 0.93–0.97). Conclusion Plasma p-tau217 shows excellent results for detecting amyloid pathology at brain level in a clinical setting with an AUC of 0.95. It is a highly specific marker of AD and increases progressively along the disease continuum. Using plasma p-tau217 as an initial diagnostic tool with cut-offs at sensitivities and specificities of 95 or 97.5% could save between 57.4–84.8% of LP/PETs with diagnostic accuracies of 95–97%. Plasma NfL increases progressively at different cognitive stages.
format Article
id doaj-art-7319eafcafeb4be8ada276bbf391624c
institution OA Journals
issn 1758-9193
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series Alzheimer’s Research & Therapy
spelling doaj-art-7319eafcafeb4be8ada276bbf391624c2025-08-20T02:10:12ZengBMCAlzheimer’s Research & Therapy1758-91932025-03-0117111610.1186/s13195-025-01719-5Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platformFrancisco Martínez-Dubarbie0Armando Guerra-Ruiz1Sara López-García2Carmen Lage3Marta Fernández-Matarrubia4Álvaro Nevado-Cáceres5María Rivera-Sánchez6Andrea Valera-Barrero7Ana Pozueta-Cantudo8María García-Martínez9Andrea Corrales-Pardo10María Bravo11Marcos López-Hoyos12Juan Irure-Ventura13Enrique Marco de Lucas14Marta Drake-Pérez15Nancy Heidy Cahuana-Santamaría16María Teresa García-Unzueta17Pascual Sánchez-Juan18Eloy Rodríguez-Rodríguez19Neurology Service, Marqués de Valdecilla University HospitalBiochemistry and Clinical Analysis Department, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalNeurology Service, Marqués de Valdecilla University HospitalInstitute for Research Marqués de Valdecilla (IDIVAL)Institute for Research Marqués de Valdecilla (IDIVAL)Institute for Research Marqués de Valdecilla (IDIVAL)Institute for Research Marqués de Valdecilla (IDIVAL)Biochemistry and Clinical Analysis Department, Marqués de Valdecilla University HospitalInstitute for Research Marqués de Valdecilla (IDIVAL)CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos IIINeurology Service, Marqués de Valdecilla University HospitalAbstract Background Plasma biomarkers for Alzheimer's disease (AD) are a promising tool for accessible and accurate biological diagnostics. However, data in clinical practice are needed to better understand their diagnostic and prognostic ability in memory unit patients. Methods We analyzed plasma phosphorylated tau at threonine 217 (p-tau217) and neuroflament light chain (NfL) levels and AD cerebrospinal fluid (CSF) biomarkers in a group of 493 subjects using the Lumipulse G600II platform. The sample includes 340 patients from our memory unit (142 dementia, 186 mild cognitive impairment, and 12 with subjective complaints) and 153 cognitively unimpaired volunteers. We have correlated plasma and CSF biomarkers; we have analyzed plasma biomarker levels as a function of clinical diagnosis, cognitive status and amyloid status. We have also studied the ability of p-tau217 to discriminate between amyloid-positive and -negative subjects according to CSF using receiver operating characteristic curves. Results Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho = -0.75; p-value < 0.001), p-tau181 (r = 0.66; p-value < 0.001), and t-tau (r = 0.59; p-value < 0.001). Plasma NfL correlated with CSF NfL (r = 0.48; p-value < 0.001). By clinical diagnosis, plasma p-tau217 levels showed to be higher in AD patients than in healthy controls (difference = 0.63 pg/ml; p-value < 0.001), FTD (difference = 0.60 pg/ml; p-value < 0.001), and nondegenerative dementias (difference = 0.61 pg/ml; p-value < 0.001). Plasma p-tau217 showed an area under the curve of 0.95 to discriminate between A + and A- subjects (95%CI 0.93–0.97). Conclusion Plasma p-tau217 shows excellent results for detecting amyloid pathology at brain level in a clinical setting with an AUC of 0.95. It is a highly specific marker of AD and increases progressively along the disease continuum. Using plasma p-tau217 as an initial diagnostic tool with cut-offs at sensitivities and specificities of 95 or 97.5% could save between 57.4–84.8% of LP/PETs with diagnostic accuracies of 95–97%. Plasma NfL increases progressively at different cognitive stages.https://doi.org/10.1186/s13195-025-01719-5Plasma p-tau217Alzheimer’s diseaseEarly diagnosisCross-sectionalHealthy controlsBiomarkers
spellingShingle Francisco Martínez-Dubarbie
Armando Guerra-Ruiz
Sara López-García
Carmen Lage
Marta Fernández-Matarrubia
Álvaro Nevado-Cáceres
María Rivera-Sánchez
Andrea Valera-Barrero
Ana Pozueta-Cantudo
María García-Martínez
Andrea Corrales-Pardo
María Bravo
Marcos López-Hoyos
Juan Irure-Ventura
Enrique Marco de Lucas
Marta Drake-Pérez
Nancy Heidy Cahuana-Santamaría
María Teresa García-Unzueta
Pascual Sánchez-Juan
Eloy Rodríguez-Rodríguez
Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
Alzheimer’s Research & Therapy
Plasma p-tau217
Alzheimer’s disease
Early diagnosis
Cross-sectional
Healthy controls
Biomarkers
title Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
title_full Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
title_fullStr Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
title_full_unstemmed Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
title_short Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
title_sort diagnostic performance of plasma p tau217 in a memory clinic cohort using the lumipulse automated platform
topic Plasma p-tau217
Alzheimer’s disease
Early diagnosis
Cross-sectional
Healthy controls
Biomarkers
url https://doi.org/10.1186/s13195-025-01719-5
work_keys_str_mv AT franciscomartinezdubarbie diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT armandoguerraruiz diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT saralopezgarcia diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT carmenlage diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT martafernandezmatarrubia diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT alvaronevadocaceres diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT mariariverasanchez diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT andreavalerabarrero diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT anapozuetacantudo diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT mariagarciamartinez diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT andreacorralespardo diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT mariabravo diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT marcoslopezhoyos diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT juanirureventura diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT enriquemarcodelucas diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT martadrakeperez diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT nancyheidycahuanasantamaria diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT mariateresagarciaunzueta diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT pascualsanchezjuan diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform
AT eloyrodriguezrodriguez diagnosticperformanceofplasmaptau217inamemorycliniccohortusingthelumipulseautomatedplatform